P/E ratio for Biolife Solutions (BLFS)
P/E ratio as of May 2024 (TTM): -9.09
According to Biolife Solutions 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.08808. At the end of 2022 the company had a P/E ratio of -5.55.
P/E ratio history for Biolife Solutions from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.55 | -97.05% |
| 2021 | -188 | -133.01% |
| 2020 | 570 | -1544.01% |
| 2019 | -39.5 | -159.05% |
| 2018 | 66.8 | -333.92% |
| 2017 | -28.6 | 876.04% |
| 2016 | -2.93 | -52.79% |
| 2015 | -6.20 | 20.98% |
| 2014 | -5.13 | -86.49% |
| 2013 | -37.9 | 210.53% |
| 2012 | -12.2 | 877.27% |
| 2011 | -1.25 | -16.67% |
| 2010 | -1.50 | -45.45% |
| 2009 | -2.75 | 266.67% |
| 2008 | -0.7500 | -50% |
| 2007 | -1.50 | -14.29% |
| 2006 | -1.75 | -41.67% |
| 2005 | -3.00 | 100% |
| 2004 | -1.50 | 118.18% |
| 2003 | -0.6875 | -122.92% |
| 2002 | 3.00 | -628.57% |
| 2001 | -0.5676 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Celanese CE | 13.1 | -244.47% | 🇺🇸 USA |
 Enanta Pharmaceuticals
ENTA | -2.18 | -76.04% | 🇺🇸 USA |
 Amyris AMRS | -0.0273 | -99.70% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.